Immunomedics (IMMU) Phase 2 Study on IMMU-132 Achieves Planned Enrollment
Tweet Send to a Friend
Immunomedics, Inc. (NASDAQ: IMMU) today announced that a single-arm Phase 2 study with sacituzumab govitecan (IMMU-132) has achieved the planned ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
